{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T04:12:58Z","timestamp":1744863178090,"version":"3.40.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,16]]},"DOI":"10.7759\/cureus.82382","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T16:48:07Z","timestamp":1744822087000},"source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of Duloxetine in the Management of Diabetic Neuropathy: A Prospective Observational Cohort Study"],"prefix":"10.7759","author":[{"given":"Muhammad","family":"Osama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maha","family":"Javaid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bilal","family":"Shahid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heema","family":".","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayesha Ghazal","family":"Jamali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bushra","family":"Anwar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taimour","family":"Mushtaq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"The global burden of diabetes","author":"Harding JL","year":"2024","unstructured":"Harding JL, Weber MB, Shaw JE. The global burden of diabetes. Textbook of Diabetes, Sixth Edition. Holt RI, Flyvbjerg A (ed): Wiley, Hoboken, USA; 2024. 28-40."},{"key":"ref2","doi-asserted-by":"crossref","DOI":"10.22207\/JPAM.19.1.52","article-title":"Exploring the co-occurrence of tuberculosis and diabetes mellitus: a global health concern","volume":"19","author":"Selvan P","year":"2025","unstructured":"Selvan P, Jayanthi NN, Vajravelu LK, Tamizharasan M, Gokulakrishnan S. Exploring the co-occurrence of tuberculosis and diabetes mellitus: a global health concern. J Pure Appl Microbiol. 2025, 19:64-73.","journal-title":"J Pure Appl Microbiol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-079513","article-title":"Epidemiology of diabetes mellitus in Pakistan: a systematic review protocol","volume":"14","author":"Hasan SU","year":"2024","unstructured":"Hasan SU, Siddiqui MA. Epidemiology of diabetes mellitus in Pakistan: a systematic review protocol. BMJ Open. 2024, 14:e079513. 10.1136\/bmjopen-2023-079513","journal-title":"BMJ Open"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1526090","article-title":"Advances in kidney disease: pathogenesis and therapeutic targets","volume":"12","author":"Boima V","year":"2025","unstructured":"Boima V, Agyekum AB, Ganatra K, et al.. Advances in kidney disease: pathogenesis and therapeutic targets. Front Med (Lausanne). 2025, 12:1526090. 10.3389\/fmed.2025.1526090","journal-title":"Front Med (Lausanne)"},{"key":"ref5","article-title":"Postural control in diabetic peripheral neuropathy: a narrative review","volume":"16","author":"Bhatt U","year":"2022","unstructured":"Bhatt U, Mehta M, Kumar GP. Postural control in diabetic peripheral neuropathy: a narrative review. J Clin Diagn Res. 2022, 16:YE06-YE14.","journal-title":"J Clin Diagn Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S370050","article-title":"Painful diabetic peripheral neuropathy: practical guidance and challenges for clinical management","volume":"16","author":"Preston FG","year":"2023","unstructured":"Preston FG, Riley DR, Azmi S, Alam U. Painful diabetic peripheral neuropathy: practical guidance and challenges for clinical management. Diabetes Metab Syndr Obes. 2023, 16:1595-612. 10.2147\/DMSO.S370050","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1265372","article-title":"Diabetic peripheral neuropathy: pathogenetic mechanisms and treatment","volume":"14","author":"Zhu J","year":"2023","unstructured":"Zhu J, Hu Z, Luo Y, et al.. Diabetic peripheral neuropathy: pathogenetic mechanisms and treatment. Front Endocrinol (Lausanne). 2023, 14:1265372. 10.3389\/fendo.2023.1265372","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.69028","article-title":"Neuropharmacology of neuropathic pain: a systematic review","volume":"16","author":"Mian MU","year":"2024","unstructured":"Mian MU, Afzal M, Butt AA, et al.. Neuropharmacology of neuropathic pain: a systematic review. Cureus. 2024, 16:e69028. 10.7759\/cureus.69028","journal-title":"Cureus"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-023-02185-6","article-title":"Efficacy and safety of duloxetine in painful diabetic peripheral neuropathy: a systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Wu CS","year":"2023","unstructured":"Wu CS, Huang YJ, Ko YC, Lee CH. Efficacy and safety of duloxetine in painful diabetic peripheral neuropathy: a systematic review and meta-analysis of randomized controlled trials. Syst Rev. 2023, 12:53. 10.1186\/s13643-023-02185-6","journal-title":"Syst Rev"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1177\/1073858420974336","article-title":"Monoamines: dopamine, norepinephrine, and serotonin, beyond modulation, \"switches\" that alter the state of target networks","volume":"28","author":"Azizi SA","year":"2022","unstructured":"Azizi SA. Monoamines: dopamine, norepinephrine, and serotonin, beyond modulation, \"switches\" that alter the state of target networks. Neuroscientist. 2022, 28:121-43. 10.1177\/1073858420974336","journal-title":"Neuroscientist"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci13020333","article-title":"Current opinions about the use of duloxetine: results from a survey aimed at psychiatrists","volume":"13","author":"Alvarez-Mon MA","year":"2023","unstructured":"Alvarez-Mon MA, Garc\u00eda-Montero C, Fraile-Martinez O, et al.. Current opinions about the use of duloxetine: results from a survey aimed at psychiatrists. Brain Sci. 2023, 13:333. 10.3390\/brainsci13020333","journal-title":"Brain Sci"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.13153","article-title":"Diabetic neuropathy in children and youth: new and emerging risk factors","volume":"22","author":"Akinci G","year":"2021","unstructured":"Akinci G, Savelieff MG, Gallagher G, Callaghan BC, Feldman EL. Diabetic neuropathy in children and youth: new and emerging risk factors. Pediatr Diabetes. 2021, 22:132-47. 10.1111\/pedi.13153","journal-title":"Pediatr Diabetes"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.671257","article-title":"Advances in screening, early diagnosis and accurate staging of diabetic neuropathy","volume":"12","author":"Carmichael J","year":"2021","unstructured":"Carmichael J, Fadavi H, Ishibashi F, Shore AC, Tavakoli M. Advances in screening, early diagnosis and accurate staging of diabetic neuropathy. Front Endocrinol (Lausanne). 2021, 12:671257. 10.3389\/fendo.2021.671257","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s11764-021-01012-y","article-title":"The impact of obesity on neuropathy outcomes for paclitaxel- and oxaliplatin-treated cancer survivors","volume":"16","author":"Timmins HC","year":"2022","unstructured":"Timmins HC, Li T, Goldstein D, et al.. The impact of obesity on neuropathy outcomes for paclitaxel- and oxaliplatin-treated cancer survivors. J Cancer Surviv. 2022, 16:223-32. 10.1007\/s11764-021-01012-y","journal-title":"J Cancer Surviv"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.36695","article-title":"Hemoglobin, body mass index, and age as risk factors for paclitaxel- and oxaliplatin-induced peripheral neuropathy","volume":"4","author":"Mizrahi D","year":"2021","unstructured":"Mizrahi D, Park SB, Li T, et al.. Hemoglobin, body mass index, and age as risk factors for paclitaxel- and oxaliplatin-induced peripheral neuropathy. JAMA Netw Open. 2021, 4:e2036695. 10.1001\/jamanetworkopen.2020.36695","journal-title":"JAMA Netw Open"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-050182","article-title":"Phase III, international, multicentre, double-blind, dose increment, parallel-arm, randomised controlled trial of duloxetine versus pregabalin for opioid-unresponsive neuropathic cancer pain: a JORTC-PAL16 trial protocol","volume":"12","author":"Matsuoka H","year":"2022","unstructured":"Matsuoka H, Clark K, Fazekas B, et al.. Phase III, international, multicentre, double-blind, dose increment, parallel-arm, randomised controlled trial of duloxetine versus pregabalin for opioid-unresponsive neuropathic cancer pain: a JORTC-PAL16 trial protocol. BMJ Open. 2022, 12:e050182. 10.1136\/bmjopen-2021-050182","journal-title":"BMJ Open"},{"key":"ref17","article-title":"Role of duloxetine in neuropathic pain: a clinical impact, mechanism, challenges in formulation development to safety concern","volume":"15","author":"Dash L","year":"2022","unstructured":"Dash L, Kumar B, Anupriya, et al.. Role of duloxetine in neuropathic pain: a clinical impact, mechanism, challenges in formulation development to safety concern. Res J Pharm Technol. 2022, 15:1852-1862.","journal-title":"Res J Pharm Technol"},{"key":"ref18","article-title":"Effectiveness and safety of amitriptyline, duloxetine, and pregabalin in painful diabetic neuropathy: an observational study","volume":"13","author":"Sumedhan SV","year":"2023","unstructured":"Sumedhan SV, Wilson V, Manoj P, Rajamony PN. Effectiveness and safety of amitriptyline, duloxetine, and pregabalin in painful diabetic neuropathy: an observational study. Nat J Physiol Pharm Pharmacol. 2023, 13:1374-1379.","journal-title":"Nat J Physiol Pharm Pharmacol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2005.00061.x","article-title":"A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain","volume":"6","author":"Raskin J","year":"2005","unstructured":"Raskin J, Pritchett YL, Wang F, D'Souza DN, Waninger AL, Iyengar S, Wernicke JF. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med. 2005, 6:346-56. 10.1111\/j.1526-4637.2005.00061.x","journal-title":"Pain Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-019-00882-6","article-title":"Comparison of the efficacy and safety of pregabalin and duloxetine in taxane-induced sensory neuropathy: a randomized controlled trial","volume":"40","author":"Salehifar E","year":"2020","unstructured":"Salehifar E, Janbabaei G, Hendouei N, Alipour A, Tabrizi N, Avan R. Comparison of the efficacy and safety of pregabalin and duloxetine in taxane-induced sensory neuropathy: a randomized controlled trial. Clin Drug Investig. 2020, 40:249-57. 10.1007\/s40261-019-00882-6","journal-title":"Clin Drug Investig"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-022-05135-y","article-title":"Effectiveness and adverse effects of the use of mirtazapine as compared to duloxetine for fibromyalgia: real-life data from a retrospective cohort","volume":"42","author":"Mehta P","year":"2022","unstructured":"Mehta P, Basu A, Ahmed S. Effectiveness and adverse effects of the use of mirtazapine as compared to duloxetine for fibromyalgia: real-life data from a retrospective cohort. Rheumatol Int. 2022, 42:1549-54. 10.1007\/s00296-022-05135-y","journal-title":"Rheumatol Int"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-86366-0","article-title":"Genotoxic and oxidative effect of duloxetine on mouse brain and liver tissues","volume":"11","author":"\u00c1lvarez-Gonz\u00e1lez I","year":"2021","unstructured":"\u00c1lvarez-Gonz\u00e1lez I, Camacho-Cantera S, G\u00f3mez-Gonz\u00e1lez P, et al.. Genotoxic and oxidative effect of duloxetine on mouse brain and liver tissues. Sci Rep. 2021, 11:6897. 10.1038\/s41598-021-86366-0","journal-title":"Sci Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/357562-efficacy-of-duloxetine-in-the-management-of-diabetic-neuropathy-a-prospective-observational-cohort-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T16:48:13Z","timestamp":1744822093000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/357562-efficacy-of-duloxetine-in-the-management-of-diabetic-neuropathy-a-prospective-observational-cohort-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.82382","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,16]]}}}